💡 Company received trading approval for 13 lakh equity shares allotted under preferential allotment, indicating successful fundraise completion.

What Happened

Vilin Bio Med Limited has informed the National Stock Exchange that it has received trading approval for 13,00,000 equity shares of face value Rs. 10 each. These shares were allotted on a preferential allotment basis. The company filed this disclosure pursuant to Regulation 30 of SEBI LODR Regulations, 2015.

Key Details

Why It Matters

Receiving trading approval from NSE for shares allotted under preferential allotment is a significant step that completes the fundraise process. This allows the newly issued shares to be traded on the exchange, providing liquidity to the allottees. Preferential allotments are typically made to strategic investors or institutions, and the completion of this regulatory step indicates the funds have been received and the capital infusion is now fully operational. This can strengthen the company's balance sheet and potentially fund growth initiatives.

Disclaimer: This is publicly available information sourced from NSE. Not investment advice.

Get signals like this instantly

Free Telegram alerts within 2 minutes of NSE filing

Join SuperStock Free
← Back to all analysis